# ScandiDos > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/scandidos). ## Overview ScandiDos is a Swedish medical technology company based in Uppsala that develops and sells measurement phantoms and quality-assurance systems for radiotherapy. Its products are used to verify treatment plans and dose delivery in cancer care, with sales handled directly in some markets and through distributors in others. ## Products & services • Delta4 radiotherapy QA systems • Delta4 Insight software and platform • Stereotactic measurement phantoms • Service, support, and product maintenance • Product registration and regulatory support - **Radiotherapy quality assurance systems** (70%) — Hardware and software used to verify treatment plans and dose delivery in radiation therapy. - **Measurement phantoms** (20%) — Physical phantom products used for calibration and verification in radiotherapy workflows. - **Software and digital verification tools** (5%) — Software platforms that support treatment-plan analysis and QA workflows. - **Service and support** (5%) — Installation, maintenance, training, and technical support for installed systems. - Delta4 radiotherapy QA systems - Delta4 Insight software and platform - Stereotactic measurement phantoms - Service, support, and product maintenance - Product registration and regulatory support ## Customers ScandiDos sells to hospitals, cancer centers, and radiotherapy clinics that need to verify treatment plans and dose accuracy before patient treatment. It also serves public healthcare systems, private clinics, and foundation-owned institutions, often through local distributors in export markets. Customers buy the company’s systems to improve treatment safety, meet quality standards, and support advanced radiotherapy techniques. - **Hospitals and cancer centers** (primary) — Buy Delta4 systems and phantoms to verify radiotherapy plans and dose delivery before treatment. - **Public healthcare providers** (primary) — Purchase QA equipment for standardized cancer-treatment workflows and compliance needs. - **Private clinics** (secondary) — Buy verification systems to support precision radiotherapy and efficient patient throughput. - **Distributors and channel partners** (secondary) — Resell ScandiDos products in markets where the company does not sell directly. - Hospitals and cancer centers running radiotherapy departments - Private and public clinics needing treatment-plan verification - Foundation-owned healthcare institutions with QA requirements - Distributors serving local radiotherapy markets - Customers seeking regulatory-compliant dose verification tools ## Geography ScandiDos is headquartered in Uppsala, Sweden, and its development and support functions are centered there. The company sells directly or through subsidiaries in the Nordics, France, and the United States, while a wider distributor network covers other markets, especially in Asia. The business is exposed to mature replacement demand in Western markets and to capital spending cycles in faster-growing Asian radiotherapy markets. - **Europe** (45%) — Direct sales in the Nordics and France; broader European presence via distributors. - **North America** (30%) — The company states it is established on many leading clinics in North America. - **Asia** (25%) — Asia is described as the main expansion market, with Japan specifically highlighted. - Head office and core R&D are in Uppsala, Sweden - Direct sales in the Nordics, France, and the United States - Local distributors cover roughly 40 other markets - Asia is an important growth region for radiotherapy investment - Western Europe and North America are more mature replacement markets ## Strategy ScandiDos focuses on radiotherapy quality assurance products that support precise and safe cancer treatment, with Delta4 Insight and newer stereotactic products extending the platform. The company’s commercial model combines direct sales in selected markets with distributors elsewhere, allowing it to reach installed radiotherapy centers globally. Its strategy also depends on product development, regulatory approvals, and maintaining relevance as radiotherapy techniques become more advanced. - **Grow in Asia** (medium-term) — Asian radiotherapy markets still require new equipment and offer more expansion than mature Western markets. - **Protect and renew the installed base** (short-term) — Western Europe and North America are mature, so growth depends on replacement sales and customer retention. - **Advance product development** (medium-term) — New products help the company stay relevant as radiotherapy techniques become more complex. - **Preserve market access through approvals and partners** (short-term) — Regulatory clearance and distributor coverage are essential to selling in multiple countries. - Expand in Asia where radiotherapy investment remains strong - Defend installed base in mature Western markets through replacements - Develop new QA products such as Delta4 Insight and Delta4 SRS Pro - Use distributors and channel partners to broaden global reach - Maintain regulatory approvals to support market access ## Risks ScandiDos faces exposure to currency movements because much of its sales are invoiced in euros and U.S. dollars, and it also depends on key personnel and distributor relationships. As a medical technology company, it must navigate regulatory approvals and product-registration timelines, while the value of capitalized intangibles depends on successful commercialization of new products. The business is also exposed to the usual radiotherapy-market risks of long sales cycles, customer budget timing, and technology adoption. - **Foreign exchange volatility** [high] — Most sales are invoiced in euros and U.S. dollars, creating translation and transaction exposure. - **Key-person dependence** [high] — The company relies on specialized technical and regulatory staff in a niche medtech business. - **Distributor and partner concentration** [medium] — Sales in many markets depend on local distributors and industry partners. - **Regulatory approval delays** [high] — Product registrations and renewals can take longer than planned in different countries. - **Impairment of capitalized intangibles** [high] — Delta4 Insight and other development assets depend on future commercialization success. - FX risk from euro and U.S. dollar invoicing - Dependence on key employees and succession planning - Distributor dependence in many export markets - Regulatory approval delays can postpone sales - Intangible asset impairment risk if product sales lag ## Accounting The main accounting judgments for ScandiDos relate to capitalization and impairment of development-related intangible assets, especially products in commercialization. Revenue can also be affected by timing around product delivery, regulatory approvals, and distributor arrangements, while foreign-exchange hedging introduces derivative accounting and fair-value effects. Investors should also watch provisions, related-party transactions, and the treatment of company guarantees and pledged security. - **Development intangible asset impairment** — Could accelerate write-downs if sales targets are missed - **Foreign exchange hedging** — Can create gains/losses in other comprehensive income or P&L depending on hedge treatment - **Revenue recognition timing** — Quarterly revenue can shift with shipment and approval timing - **Related-party transactions** — Relevant for assessing transfer pricing and governance - Capitalized development assets and impairment testing - Revenue timing for direct sales and distributor channels - Derivative accounting for FX hedges and fair-value changes - Regulatory approval timing can affect shipment and revenue recognition - Pledged security and related-party transactions require disclosure --- *Last updated: 2026-08-11T04:04:55.655927+00:00*